Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study
Open accessThe DOI matches its Crossref record; 10 of the 14 references it cites were found in a registry or an index.
Abstract
Background HannaH (NCT00950300) was a phase III, randomized, international, open-label study that compared pharmacokinetics (PK), efficacy, and safety of two different trastuzumab formulations [subcutaneous (s.c.) and intravenous (i.v.)] in HER2-positive, operable, locally advanced, or inflammatory breast cancer in the neoadjuvant/adjuvant setting. The co-primary end points, to show noninferiority of s.c. versus i.v. trastuzumab in terms of serum concentration (Ctrough) and pathologic complete response (pCR) were met; safety profiles were comparable at 12 months' median follow-up. Secondary end points included safety and tolerability, PK profile, immunogenicity, and event-free survival (EFS). We now report updated safety and efficacy data after a median follow-up of 20 months.Patients and methods Patients (N = 596) were treated with eight cycles of neoadjuvant chemotherapy, administered concurrently with 3-weekly s.c. trastuzumab (fixed dose of 600 mg) or the standard weight-based i.v. method. Following surgery, patients continued trastuzumab treatment to complete 1 year of therapy. Updated analyses of PK, efficacy, safety, and immunogenicity data were carried out.Results s.c. trastuzumab was generally well tolerated and the incidence of adverse events (AEs), including grade 3 or 4 AEs, between treatment groups was comparable. A slightly higher incidence of serious AEs (SAEs), mainly due to infections, was reported with s.c. treatment {64 [21.5%; 95% confidence interval (CI) 17.0%-26.7%] versus 42 (14.1%; 95% CI 10.4%-18.6%) in the i.v. group}; however, the differences were small and often based on rare events, with no observable pattern across reported events. An early analysis of EFS showed rates of 95% in both groups 1 year postrandomization. Exploratory analyses did not reveal an association between toxicity and body weight or exposure.Conclusions Overall, the safety profile of s.c. trastuzumab was consistent with the previously published data from HannaH and the known safety profile of i.v. trastuzumab. EFS rates were comparable between the i.v. and s.c. groups.Clinical trial number NCT00950300.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SC trastuzumab was shown to be non-inferior to IV, for both co-primary endpoints (serum trough concentration at pre-dose cycle 8 and pathologic complete response rates), demonstrating that the SC formulation is a valid treatment alternative to IV [31–34].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt303 · Cited by 3,746
Cardoso, F., Fallowfield, L., Costa, A., Castiglione, M., & Senkus, E. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr372 · Cited by 596
Cardoso, F., Harbeck, N., Fallowfield, L., Kyriakides, S., & Senkus, E. (2012) · Annals of Oncology · doi:10.1093/annonc/mds232 · Cited by 485
Ismael, G., Hegg, R., Muehlbauer, S., Heinzmann, D., Lum, B., Kim, S.-B., Pienkowski, T., Lichinitser, M., Semiglazov, V., Melichar, B., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70329-7 · Cited by 351
Self-citationPivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70383-8 · Cited by 230
Self-citationWynne, C., Ellis-Pegler, R. B., Waaka, D., Schwabe, C., Lehle, M., Heinzmann, D., Mangat, R., Li, C., Dick, A. E., Cranshaw, N. A., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2273-z · Cited by 27
Self-citationPivot, X. B., Gligorov, J., Müller, V., Verma, S., Knoop, A. S., Curigliano, G., Camcı, C., Jenkins, V. A., Scotto, N., Osborne, S., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.sabcs13-p4-12-11 · Cited by 10
Self-citationHegg, R., Pienkowski, T., Chen, S., Staroslawska, E., Falcon, S., Kovalenko, N., Al-Sakaff, N., Heinzmann, D., Kolaitis, G., & Ismael, G. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(20)32835-0 · Cited by 9
Self-citationGligorov, J., Azim, H. A., Ataseven, B., Delaurentiis, M., Jung, K. H., Herbst, F., Llombart‐Cussac, A., Manikhas, A., Osborne, S., & Pivot, X. B. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(20)32881-7 · Cited by 6
Self-citationJackisch, C., Dank, M., Frasci, G., Park, K. H., Lopez, R. I., Johnston, M., Heinzmann, D., Weber, H., & Ismael, G. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(20)32833-7 · Cited by 6
Self-citation
Research works printed but not linked: 7
- von Minckwitz G, Mobus V, Schneeweiss A et al. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol 2013; 31: 3531-3539.
- Kristensen B, Ejlertsen B, Mouridsen HT et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 2008; 47: 740-746.
- Kesmodel SB, Sabnis GJ, Chumsri S, Brodie AM. Combined cancer therapy: strategies to overcome acquired aromatase inhibitor resistance. Curr Pharm Des 2014; 20: 6575-6583.
- Pagani O, Regan MM, Walley BA et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371: 107-118.
- Pfeiler G, Koenigsberg R, Fesl C et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol 2011; 29: 2653-2659. references
- Melichar B, Stroyakovskiy D, Ahn JS et al. Pathological complete response to trastuzumab subcutaneous fixed-dose formulation in the HannaH study: Subgroup analysis of patient demographics and tumour characteristics and influence of body weight and serum trough concentration of trastuzumab. In 37th European Society for Medical Oncology Conference (Abstract 254PD), Vienna, Austria, 28 September-2 October 2012.
- Haller MR. Converting intravenous dosing to subcutaneous dosing with recombinant human hyaluronidase. Pharm Tech 2007; 10: 861-864.
Cited by
Development of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085
Zhou, Q., Jin, J.-F., Zhu, L.-L., Chen, M., Xu, H.-M., Wang, H.-F., Feng, X.-Q., & Zhu, X.-P. (2015) · Patient Preference and Adherence · doi:10.2147/ppa.s87271 · Cited by 296
Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics
Davda, J., Declerck, P., Hu-Lieskovan, S., Hickling, T. P., Jacobs, I. A., Chou, J., Salek-Ardakani, S., & Kraynov, E. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0586-0 · Cited by 178
Locke, K. W., Maneval, D. C., & LaBarre, M. J. (2019) · Drug Delivery · doi:10.1080/10717544.2018.1551442 · Cited by 177
Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges
van Brummelen, E. M. J., Ros, W., Wolbink, G., Beijnen, J. H., & Schellens, J. H. M. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0061 · Cited by 150
Metadata
- Authors
- Jackisch, C., Kim, S.-B., Semiglazov, V., Melichar, B., Pivot, X., Hillenbach, C., Stroyakovskiy, D., Lum, B. L., Elliott, R., Weber, H. A., & Ismael, G.
- Affiliations
- Sana Klinikum Offenbach (DE)
- Asan Medical Center (KR)
- Palacký University Olomouc (CZ)
- Centre Hospitalier Universitaire de Besançon (FR)
- F. Hoffmann-La Roche AG (CH)
- Moscow City Oncology Hospital №62 (RU)
- Genentech (US)
- Hospital Amaral Carvalho (BR)
- Corresponding author
- Jackisch, C.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 26
- Issue
- 2
- Pages
- 320-325
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2115527794
- Cited by
- 114
- References
- 14
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 6 · 2023: 8 · 2022: 3 · 2021: 8 · 2020: 9 · 2019: 17 · 2018: 20 · 2017: 11 · 2016: 12 · 2015: 12
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 1801 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Javna Agencija za Raziskovalno Dejavnost RS
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- trastuzumab, subcutaneous administration, intravenous administration, HER2-positive breast cancer, neoadjuvant therapy, adjuvant therapy, pathological complete response, pharmacokinetics, immunogenicity, adverse events, event-free survival, body weight, drug exposure, locally advanced breast cancer, inflammatory breast cancer, non-inferiority, infection, weight-based dosing
- MeSH terms
- Trastuzumab, Adult, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Infusions, Intravenous, Injections, Subcutaneous, Middle Aged, Erb-b2 Receptor Tyrosine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.